Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.8 million, up 64.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 210.72% YoY), and the FY2025 annual result was -$1.8 million, up 17.2% from the prior year.
• Change in Accured Expenses retreated to -$1.8 million in Q1 2026 per DTIL's latest filing, from $2.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.4 million in Q2 2022 and troughed at -$5.8 million in Q1 2024.
• A 5-year average of -$483882.4 and a median of $474000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses slumped 139.98% in 2022, then soared 1478.85% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $421000.0 in 2022, then surged by 464.61% to $2.4 million in 2023, then tumbled by 106.56% to -$156000.0 in 2024, then soared by 1478.85% to $2.2 million in 2025, then sank by 183.5% to -$1.8 million in 2026.
• Business Quant data shows DTIL's Change in Accured Expenses at -$1.8 million in Q1 2026, $2.2 million in Q4 2025, and $528000.0 in Q3 2025.